Eritoran

Summary

Eritoran (CHEMBL501259) is a phase-3 clinical-stage small molecule; indicated across 4 conditions including pneumonia and influenza.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Indications: 4 conditions
• Clinical trials: 3
• Chemistry: 1313.7 Da · C66H126N2O19P2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL501259
Name	Eritoran
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	6912404
ChEBI	CHEBI:68609
Molecular formula	C66H126N2O19P2
Molecular weight	1313.7
InChIKey	BPSMYQFMCXXNPC-MFCPCZTFSA-N

SMILES: CCCCCCCCCCCC(=O)CC(=O)N[C@@H]1[C@H]([C@@H]([C@H](O[C@@H]1OP(=O)(O)O)CO[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)COC)OP(=O)(O)O)OCC[C@@H](CCCCCCC)OC)NC(=O)CCCCCCCCC/C=C\CCCCCC)O)OCCCCCCCCCC

IUPAC name: [(2R,3R,4R,5S,6R)-4-decoxy-5-hydroxy-6-[[(2R,3R,4R,5S,6R)-4-[(3R)-3-methoxydecoxy]-6-(methoxymethyl)-3-[[(Z)-octadec-11-enoyl]amino]-5-phosphonooxyoxan-2-yl]oxymethyl]-3-(3-oxotetradecanoylamino)oxan-2-yl] dihydrogen phosphate

ChEBI definition: A lipid A derivative used for the treatment of severe sepsis.

Also known as: Eritoran, ERITORAN

Parent form; salt/anhydrous children: CHEMBL3301672

Patent coverage: 166 distinct patent families (359 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 1 (assay-derived). Sample: Toll-like receptor 4.

Bioactivity

ChEMBL activities: 1 potent at pChembl ≥ 5 of 1 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
TLR4	8.82	IC50	1.5	nM	CHEMBL_ACT_18916444

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

4 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
pneumonia	3	MONDO:0005249	EFO:0003106
influenza	3	MONDO:0005812	EFO:0007328
severe acute respiratory syndrome	3	MONDO:0005091	MONDO:0100096

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 3.

Phase distribution

Phase	Trials
PHASE2	2
PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02735707	PHASE3	RECRUITING	Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia
NCT02267317	PHASE2	TERMINATED	The Effect of TLR4 Inhibition in Obese and Type 2 Diabetic Subjects
NCT02321111	PHASE2	COMPLETED	The Role of TLR4 on Lipid-induced Insulin Resistance

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).